India
· Delayed Price · Currency is INR Marksans Pharma Statistics
Total Valuation
Marksans Pharma has a market cap or net worth of INR 138.17 billion. The enterprise value is 133.67 billion.
| Market Cap | 138.17B |
| Enterprise Value | 133.67B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | Sep 17, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.16% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 204.31M |
Valuation Ratios
The trailing PE ratio is 39.82.
| PE Ratio | 39.82 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 6.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.39, with an EV/FCF ratio of 256.98.
| EV / Earnings | 38.52 |
| EV / Sales | 5.62 |
| EV / EBITDA | 26.39 |
| EV / EBIT | 31.54 |
| EV / FCF | 256.98 |
Financial Position
The company has a current ratio of 4.68, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.68 |
| Quick Ratio | 2.79 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.39 |
| Debt / FCF | 3.81 |
| Interest Coverage | 31.25 |
Financial Efficiency
Return on equity (ROE) is 16.54% and return on invested capital (ROIC) is 11.74%.
| Return on Equity (ROE) | 16.54% |
| Return on Assets (ROA) | 10.14% |
| Return on Capital (ROIC) | 11.74% |
| Revenue Per Employee | 20.85M |
| Profits Per Employee | 3.04M |
| Employee Count | 1,141 |
| Asset Turnover | 0.91 |
| Inventory Turnover | 1.70 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +97.10% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +97.10% |
| 50-Day Moving Average | 305.66 |
| 200-Day Moving Average | 221.12 |
| Relative Strength Index (RSI) | 41.89 |
| Average Volume (20 Days) | 224,294 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Marksans Pharma had revenue of INR 23.79 billion and earned 3.47 billion in profits. Earnings per share was 7.65.
| Revenue | 23.79B |
| Gross Profit | 12.85B |
| Operating Income | 4.24B |
| Pretax Income | 4.58B |
| Net Income | 3.47B |
| EBITDA | 4.82B |
| EBIT | 4.24B |
| Earnings Per Share (EPS) | 7.65 |
Balance Sheet
The company has 6.72 billion in cash and 1.98 billion in debt, giving a net cash position of 4.74 billion.
| Cash & Cash Equivalents | 6.72B |
| Total Debt | 1.98B |
| Net Cash | 4.74B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 23.05B |
| Book Value Per Share | 50.24 |
| Working Capital | 16.34B |
Cash Flow
In the last 12 months, operating cash flow was 2.17 billion and capital expenditures -1.65 billion, giving a free cash flow of 520.15 million.
| Operating Cash Flow | 2.17B |
| Capital Expenditures | -1.65B |
| Free Cash Flow | 520.15M |
| FCF Per Share | n/a |
Margins
Gross margin is 54.01%, with operating and profit margins of 17.82% and 14.59%.
| Gross Margin | 54.01% |
| Operating Margin | 17.82% |
| Pretax Margin | 19.24% |
| Profit Margin | 14.59% |
| EBITDA Margin | 20.26% |
| EBIT Margin | 17.82% |
| FCF Margin | 2.19% |
Dividends & Yields
This stock pays an annual dividend of 0.60, which amounts to a dividend yield of 0.19%.
| Dividend Per Share | 0.60 |
| Dividend Yield | 0.19% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 7.84% |
| Buyback Yield | -3.16% |
| Shareholder Yield | -2.96% |
| Earnings Yield | 2.52% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on March 11, 2008. It was a forward split with a ratio of 10.
| Last Split Date | Mar 11, 2008 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |